Global Blood-Based Biomarker Market Top Companies Study - Diadem srl, Proteomedix, Cleveland Diagnostics, F. Hoffmann-La Roche Ltd.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Blood-Based Biomarker Market - (By Type (Screening Biomarker, Diagnosis Biomarker, Others), By Disease (Cancer, Neurological Disorders, Others), By Application (Diagnostics, Drug Discovery, Personalized Medicine)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Blood-Based Biomarker Market is valued at US$ 18.25 Bn in 2022, and it is expected to reach US$ 51.71 Bn by 2031, with a CAGR of 12.44% during the forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2244

Biomarkers are defined as measurable biological molecules, genes, or characteristics found in living organisms that provide critical insights into normal or pathological biological processes, disease progression, and therapeutic response. These indicators are typically detected and quantified in biological fluids or tissues, including blood, urine, saliva, and biopsied specimens.

The global biomarkers market is experiencing significant growth, primarily driven by the increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, neurological conditions, and infectious diseases. In parallel, advancements in high-throughput omics technologies-particularly proteomics and metabolomics-are accelerating biomarker discovery and analysis, facilitating broader clinical and research applications.

Technological innovations have significantly enhanced the identification of novel biomarkers and the development of biomarker-based diagnostics, including biomarker signatures, which are improving prognostic capabilities, especially in the context of neurological diseases. Additionally, the growing burden of infectious diseases, the emergence of rare genetic disorders, and the rising geriatric population are expected to further support market expansion.

Biomarkers also play an essential role in pharmaceutical research, where they are employed in drug development, safety profiling, and precision diagnostics. Their utility in detecting disease presence, assessing progression risk, and tailoring personalized treatment strategies underscores their importance across both clinical and translational medicine.

List of Prominent Players in the Blood-Based Biomarker Market:
• Diadem srl
• Proteomedix
• Cleveland Diagnostics
• F. Hoffmann-La Roche Ltd.
• GENFIT
• Nutech Cancer Biomarkers India Pvt Ltd.
• SysmOex Corporation,
• Minomic,
• Creative Diagnostics,
• Eisai Co., Ltd.,
• C2N Diagnostics
• Others

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
The biomarker market is experiencing robust growth, primarily propelled by ongoing scientific advancements, increased awareness of biomarker potential, the promise of enhanced therapeutic efficacy, and supportive regulatory environments. Biomarkers are transforming the healthcare landscape by enabling precise diagnosis, facilitating early detection, guiding timely therapeutic interventions, and supporting continuous monitoring of disease progression. Consequently, pharmaceutical companies, biotechnology enterprises, academic research institutions, and government bodies are making significant investments aimed at optimizing patient care outcomes while concurrently reducing overall healthcare expenditures. These concerted efforts are expected to drive continued expansion of the biomarker market.

Challenges:
Despite the promising outlook, the biomarker market faces notable challenges, particularly in establishing the cost-effectiveness and clinical utility of biomarker-based tests. Demonstrating diagnostic accuracy, improved clinical outcomes, and healthcare cost savings is essential to support broader adoption. However, the process of validating novel biomarkers is resource-intensive, both in terms of time and financial investment. Furthermore, limited or delayed reimbursement for biomarker testing can impede market growth, especially for newly introduced or cutting-edge diagnostic solutions.

Regional Trends:
North America is projected to command a dominant share of the global biomarker market, with strong revenue performance and a high compound annual growth rate (CAGR) anticipated over the forecast period. The region benefits from a mature biotechnology and pharmaceutical sector, which continues to channel substantial investment into biomarker research and development. This, combined with a well-established healthcare infrastructure and favorable regulatory frameworks, supports the widespread adoption of biomarker-based diagnostics and therapeutics. Globally, the market for blood-based biomarkers is also expected to witness steady growth, underpinned by the rising incidence of cancer and neurological disorders.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2244

Recent Developments:
• In May 2023, Proteomedix made an official declaration regarding the agreement that has been reached, whereby Labcorp will take sole responsibility for developing and commercialising the Proclarix® Prostate Specific Antigen (PSA) test within the United States. Proclarix was developed to assist in identifying the risk of prostate cancer in men without a cancer suspicion who had an elevated total prostate-specific antigen (PSA) and a digital rectal examination demonstrating an enlarged prostate volume. The procedure utilized the identical blood sample as the PSA test. When applicable, the test provided a non-invasive substitute for a prostate biopsy, a procedure known for its substantial adverse effects.

Segmentation of Blood-Based Biomarker Market-
By Type-
• Screening Biomarker
• Diagnosis Biomarker
• Others
By Disease-
• Cancer
• Neurological Disorders
• Others
By Application-
• Diagnostics
• Drug Discovery
• Personalized Medicine
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/blood-based-biomarker-market/2244

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.